Literature DB >> 18573832

Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland.

O M Gray1, G V McDonnell, S A Hawkins.   

Abstract

BACKGROUND: Northern Ireland is recognized as an area of high risk for multiple sclerosis. The original study of Allison and Millar in 1951 found a prevalence of 51/100,000 and mean annual incidence of 2.74/100,000/year. Subsequent studies in 1961, 1986, and 1996 suggested rising prevalence--80, 138, and 168.2/100,000, respectively.
METHODS: In 2004, we surveyed the North-East of Northern Ireland (population 160,446, area 2030 km(2)) using multiple sources of case ascertainment, all satisfying the Poser criteria for definite or probable multiple sclerosis (MS) or the McDonald criteria.
RESULTS: From a provisional list of 469 cases, 370 (123 males, 247 females) were identified. The prevalence was 230.6 per 100,000 (95% CI 207.0-255.4) with significantly higher prevalence in females (300.8/100,000) than males (157.0/100,000). Direct standardization to the 1961 Northern Ireland population reduced the overall prevalence rate to 200.5/100,000 (95% CI 193.2-208.0), in females to 270.2/100,000 (95% CI 258.8-282.4) and in males to 131.1/100,000 (95% CI 122.8-139.9). In 1996, incidence had risen to 9.3/100,000/year (14 cases in population of 151,000) with a higher incidence in females (10.3/100,000/year) than males (8.3/100,000/year).
CONCLUSIONS: Northern Ireland continues to have a rising prevalence of MS. The increase in incidence suggests a true increase in the disease.

Entities:  

Mesh:

Year:  2008        PMID: 18573832     DOI: 10.1177/1352458508090663

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  A budget impact analysis of natalizumab use in Ireland.

Authors:  A Dee; M Hutchinson; D De La Harpe
Journal:  Ir J Med Sci       Date:  2011-10-20       Impact factor: 1.568

Review 2.  Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.

Authors:  B Bailey
Journal:  Ir J Med Sci       Date:  2011-02-04       Impact factor: 1.568

Review 3.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.

Authors:  Glinda S Cooper; Milele L K Bynum; Emily C Somers
Journal:  J Autoimmun       Date:  2009-10-09       Impact factor: 7.094

4.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

Review 5.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

6.  A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway.

Authors:  N Grytten; J H Aarseth; H M B Lunde; K M Myhr
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-24       Impact factor: 10.154

Review 7.  Prevalence of multiple sclerosis in Latin America and its relationship with European migration.

Authors:  Edgar Correa; Víctor Paredes; Braulio Martínez
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-09-02

8.  The prevalence of MS in the United States: A population-based estimate using health claims data.

Authors:  Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca
Journal:  Neurology       Date:  2019-02-15       Impact factor: 9.910

9.  Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet Neurol       Date:  2019-01-21       Impact factor: 44.182

Review 10.  Increased Female MS Incidence and Differences in Gender-Specific Risk in Medium- and High-Risk Regions in Finland from 1981-2010.

Authors:  Markus Holmberg; Annukka Murtonen; Irina Elovaara; Marja-Liisa Sumelahti
Journal:  Mult Scler Int       Date:  2013-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.